120 related articles for article (PubMed ID: 32663452)
41. Discovery of Tarantula Venom-Derived Na
Wu B; Murray JK; Andrews KL; Sham K; Long J; Aral J; Ligutti J; Amagasu S; Liu D; Zou A; Min X; Wang Z; Ilch CP; Kornecook TJ; Lin MJ; Be X; Miranda LP; Moyer BD; Biswas K
J Med Chem; 2018 Nov; 61(21):9500-9512. PubMed ID: 30346167
[TBL] [Abstract][Full Text] [Related]
42. Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor.
Flinspach M; Xu Q; Piekarz AD; Fellows R; Hagan R; Gibbs A; Liu Y; Neff RA; Freedman J; Eckert WA; Zhou M; Bonesteel R; Pennington MW; Eddinger KA; Yaksh TL; Hunter M; Swanson RV; Wickenden AD
Sci Rep; 2017 Jan; 7():39662. PubMed ID: 28045073
[TBL] [Abstract][Full Text] [Related]
43. The peptide toxin δ-hexatoxin-MrIX inhibits fast inactivation of Na
Tang D; Xiao Z; Xu Y; Zeng J; Peng D; Liang S; Tang C; Liu Z
Peptides; 2018 Apr; 102():47-53. PubMed ID: 29501398
[TBL] [Abstract][Full Text] [Related]
44. The future of venoms-based drug discovery: an interview with Glenn King.
King GF; Coaker H
Future Med Chem; 2014 Oct; 6(15):1613-5. PubMed ID: 25406002
[No Abstract] [Full Text] [Related]
45. Development of Photocrosslinking Probes Based on Huwentoxin-IV to Map the Site of Interaction on Nav1.7.
Tzakoniati F; Xu H; Li T; Garcia N; Kugel C; Payandeh J; Koth CM; Tate EW
Cell Chem Biol; 2020 Mar; 27(3):306-313.e4. PubMed ID: 31732432
[TBL] [Abstract][Full Text] [Related]
46. Engineering Na
Murray JK; Wu B; Tegley CM; Nixey TE; Falsey JR; Herberich B; Yin L; Sham K; Long J; Aral J; Cheng Y; Netirojjanakul C; Doherty L; Glaus C; Ikotun T; Li H; Tran L; Soto M; Salimi-Moosavi H; Ligutti J; Amagasu S; Andrews KL; Be X; Lin MJ; Foti RS; Ilch CP; Youngblood B; Kornecook TJ; Karow M; Walker KW; Moyer BD; Biswas K; Miranda LP
ACS Chem Biol; 2019 Apr; 14(4):806-818. PubMed ID: 30875193
[TBL] [Abstract][Full Text] [Related]
47. A spider-venom peptide with multitarget activity on sodium and calcium channels alleviates chronic visceral pain in a model of irritable bowel syndrome.
Cardoso FC; Castro J; Grundy L; Schober G; Garcia-Caraballo S; Zhao T; Herzig V; King GF; Brierley SM; Lewis RJ
Pain; 2021 Feb; 162(2):569-581. PubMed ID: 32826759
[TBL] [Abstract][Full Text] [Related]
48. Mechanism of inhibition by chlorpromazine of the human pain threshold sodium channel, Na
Lee SJ; Kim DH; Hahn SJ; Waxman SG; Choi JS
Neurosci Lett; 2017 Feb; 639():1-7. PubMed ID: 28017662
[TBL] [Abstract][Full Text] [Related]
49. Spider Venom Peptide Pn3a Inhibition of Primary Afferent High Voltage-Activated Calcium Channels.
McArthur JR; Munasinghe NR; Finol-Urdaneta RK; Adams DJ; Christie MJ
Front Pharmacol; 2020; 11():633679. PubMed ID: 33584315
[TBL] [Abstract][Full Text] [Related]
50. Dynamic-clamp analysis of wild-type human Nav1.7 and erythromelalgia mutant channel L858H.
Vasylyev DV; Han C; Zhao P; Dib-Hajj S; Waxman SG
J Neurophysiol; 2014 Apr; 111(7):1429-43. PubMed ID: 24401712
[TBL] [Abstract][Full Text] [Related]
51. Oxidation differentially modulates the recombinant voltage-gated Na(+) channel α-subunits Nav1.7 and Nav1.8.
Schlüter F; Leffler A
Brain Res; 2016 Oct; 1648(Pt A):127-135. PubMed ID: 27450927
[TBL] [Abstract][Full Text] [Related]
52. The tarantula toxin β/δ-TRTX-Pre1a highlights the importance of the S1-S2 voltage-sensor region for sodium channel subtype selectivity.
Wingerd JS; Mozar CA; Ussing CA; Murali SS; Chin YK; Cristofori-Armstrong B; Durek T; Gilchrist J; Vaughan CW; Bosmans F; Adams DJ; Lewis RJ; Alewood PF; Mobli M; Christie MJ; Rash LD
Sci Rep; 2017 Apr; 7(1):974. PubMed ID: 28428547
[TBL] [Abstract][Full Text] [Related]
53. Natural mutations change the affinity of μ-theraphotoxin-Hhn2a to voltage-gated sodium channels.
Zhang F; Liu Y; Zhang C; Li J; Yang Z; Gong X; Gan Y; Chen P; Liu Z; Liang S
Toxicon; 2015 Jan; 93():24-30. PubMed ID: 25447770
[TBL] [Abstract][Full Text] [Related]
54. Fusion of Ssm6a with a protein scaffold retains selectivity on Na
Wang C; Shan B; Wang Q; Xu Q; Zhang H; Lei H
Chem Biol Drug Des; 2017 Jun; 89(6):825-833. PubMed ID: 27896920
[TBL] [Abstract][Full Text] [Related]
55. Molecular basis of the inhibition of the fast inactivation of voltage-gated sodium channel Nav1.5 by tarantula toxin Jingzhaotoxin-II.
Huang Y; Zhou X; Tang C; Zhang Y; Tao H; Chen P; Liu Z
Peptides; 2015 Jun; 68():175-82. PubMed ID: 25817910
[TBL] [Abstract][Full Text] [Related]
56. Optical electrophysiology for probing function and pharmacology of voltage-gated ion channels.
Zhang H; Reichert E; Cohen AE
Elife; 2016 May; 5():. PubMed ID: 27215841
[TBL] [Abstract][Full Text] [Related]
57. Functionalized Fullerene Targeting Human Voltage-Gated Sodium Channel, hNa
Hilder TA; Robinson A; Chung SH
ACS Chem Neurosci; 2017 Aug; 8(8):1747-1755. PubMed ID: 28586206
[TBL] [Abstract][Full Text] [Related]
58. Recombinant Expression, Functional Characterization of Two Scorpion Venom Toxins with Three Disulfide Bridges from the Chinese Scorpion Buthus martensii Karsch.
Lin S; Wang X; Hu X; Zhao Y; Zhao M; Zhang J; Cui Y
Protein Pept Lett; 2017; 24(3):235-240. PubMed ID: 28124609
[TBL] [Abstract][Full Text] [Related]
59. Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides.
Neff RA; Wickenden AD
Channels (Austin); 2021 Dec; 15(1):179-193. PubMed ID: 33427574
[TBL] [Abstract][Full Text] [Related]
60. Where cone snails and spiders meet: design of small cyclic sodium-channel inhibitors.
Peigneur S; Cheneval O; Maiti M; Leipold E; Heinemann SH; Lescrinier E; Herdewijn P; De Lima ME; Craik DJ; Schroeder CI; Tytgat J
FASEB J; 2019 Mar; 33(3):3693-3703. PubMed ID: 30509130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
